See What's Inside
Read this FREE issue now
For healthcare professionals only

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter

DHTV
Popular
Top Rated

Related Medications Videos on Diabetes Health TV

Could Byetta Become a Standalone Drug?

Craig Eberhard

Could Byetta Become a Standalone Drug?

Nuevas Pequeñas Molécula Drogas Para El Tipo 2  - Ensayos Humanos En Curso

Christoph Westphal, MD, Ph.D - CEO SIRTRIS (GSK)

Nuevas Pequeñas Molécula Drogas Para El Tipo 2  - Ensayos Humanos En Curso

Takeda Pharmaceuticals

Updated 71 weeks ago
US Sale of Generic Actos Gets FDA Nod
Aug 27, 2012 | 
The Food and Drug Administration has approved US sale of generic pioglitazone (trade name Actos) for the treatment of type 2 diabetes. Actos, originally developed and trademarked by Takeda Pharmaceuticals, works by decreasing insulin resistance in type 2 patients. The prescription drug, which belongs to the class of drugs known as thiazolidinediones (TZDs), has enjoyed great commercial success in the United States since its introduction in 1999, posting estimated sales last year of $2.7 billion.

Fatal error: Call to a member function getUrl() on a non-object in /home/diabetes/public_html/browse.php on line 54